Latest Period
Q4 2025
Security Snapshot
Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) Institutional Ownership
CUSIP: 92840H400
13F Institutional Holders and Ownership History from Q2 2023 to Q1 2026
Institutions Reporting
53
Shares (Excl. Options)
13,134,779
Price
$0.66
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- VTGN on Nasdaq
- Shares outstanding
- 39,040,476
- Price per share
- $0.57
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 13,134,779
- Total reported value
- $8,693,359
- % of total 13F portfolios
- 0%
- Share change
- -7,609,434
- Value change
- -$30,764,910
- Number of holders
- 53
- Price from insider filings
- $0.57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 92840H400.
- 53 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 53 to 4 between Q4 2025 and Q1 2026.
- Reported value moved from $8,693,359 to $173,409.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 53 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 92840H400?
CUSIP 92840H400 identifies VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92840H400:
Significant Owners of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | $3,243,796 | 4,383,508 | Commodore Capital LP | 31 Dec 2025 | |||
| BIOTECHNOLOGY VALUE FUND L P | 10% | $7,217,318 | 3,084,324 | BVF PARTNERS L P/IL | 31 Dec 2024 | |||
| GREAT POINT PARTNERS LLC | 5% | -22% | $1,521,317 | 2,055,834 | 0% | Great Point Partners, LLC | 31 Dec 2025 | |
| Nantahala Capital Management, LLC | 4.7% | -53% | $1,445,253 | -$912,064 | 1,953,045 | -39% | Nantahala Capital Management, LLC | 31 Dec 2025 |
| VANGUARD GROUP INC | 4.6% | -15% | $1,240,822 | +$93,162 | 1,824,738 | +8.1% | The Vanguard Group | 31 Dec 2025 |
| ORBIMED ADVISORS LLC | 4.2% | -23% | $1,213,378 | 1,639,700 | 0% | ORBIMED CAPITAL LLC | 31 Dec 2025 | |
| STEMPOINT CAPITAL LP | 1.5% | -84% | $456,394 | -$1,266,690 | 616,749 | -74% | StemPoint Capital LP | 31 Dec 2025 |
As of 31 Dec 2025, 53 institutional investors reported holding 13,134,779 shares of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN). This represents 34% of the company’s total 39,040,476 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) together control 32% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 7.8% | 3,060,000 | 0% | 0.04% | $2,025,414 |
| TCG Crossover Management, LLC | 6.9% | 2,676,580 | 0% | 0.06% | $1,771,628 |
| VANGUARD GROUP INC | 4.7% | 1,824,738 | +8.1% | 0% | $1,207,977 |
| ADAR1 Capital Management, LLC | 1.6% | 623,575 | +452% | 0.03% | $412,744 |
| JANE STREET GROUP, LLC | 1.4% | 527,127 | +74% | 0% | $348,905 |
| Ikarian Capital, LLC | 1.3% | 519,077 | -16% | 0.04% | $343,576 |
| BlackRock, Inc. | 1.1% | 422,759 | -0.09% | 0% | $279,824 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.9% | 352,836 | +18% | 0% | $233,605 |
| LUMINUS MANAGEMENT LLC | 0.9% | 350,000 | 0.21% | $231,665 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.86% | 334,786 | +291% | 0% | $221,595 |
| AdvisorShares Investments LLC | 0.64% | 250,188 | +21% | 0.03% | $165,599 |
| MILLENNIUM MANAGEMENT LLC | 0.5% | 197,045 | +853% | 0% | $130,424 |
| TWO SIGMA INVESTMENTS, LP | 0.5% | 195,570 | -32% | 0% | $129,448 |
| RENAISSANCE TECHNOLOGIES LLC | 0.41% | 160,791 | -62% | 0% | $106,428 |
| DIMENSIONAL FUND ADVISORS LP | 0.39% | 151,874 | +123% | 0% | $100,629 |
| TWO SIGMA ADVISERS, LP | 0.35% | 137,732 | -12% | 0% | $91,165 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.34% | 134,571 | -32% | 0% | $89,073 |
| STATE STREET CORP | 0.31% | 121,114 | +25% | 0% | $80,165 |
| GROUP ONE TRADING LLC | 0.27% | 106,137 | +267% | 0% | $70,252 |
| OMERS ADMINISTRATION Corp | 0.26% | 103,400 | 0% | $68,440 | |
| DIADEMA PARTNERS LP | 0.26% | 100,000 | -71% | 0.04% | $66,190 |
| TUDOR INVESTMENT CORP ET AL | 0.2% | 76,172 | 0% | $50,418 | |
| NORTHERN TRUST CORP | 0.19% | 72,655 | +51% | 0% | $48,090 |
| Seven Fleet Capital Management LP | 0.16% | 62,701 | 0% | 0.03% | $41,502 |
| Qube Research & Technologies Ltd | 0.15% | 60,139 | 0% | $39,806 |
Institutional Holders of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 303,427 | $173,409 | +$15,367 | $0.57 | 4 |
| 2025 Q4 | 13,134,779 | $8,693,359 | -$30,764,910 | $0.66 | 53 |
| 2025 Q3 | 23,364,193 | $81,815,600 | +$30,638,552 | $3.55 | 58 |
| 2025 Q2 | 14,875,235 | $29,750,933 | -$917,939 | $2.00 | 50 |
| 2025 Q1 | 15,325,061 | $38,287,272 | +$856,836 | $2.50 | 47 |
| 2024 Q4 | 14,903,856 | $43,958,204 | -$1,103,443 | $2.95 | 54 |
| 2024 Q3 | 14,643,797 | $44,079,533 | +$4,636,495 | $3.01 | 47 |
| 2024 Q2 | 13,044,677 | $45,399,902 | -$5,789,213 | $3.48 | 42 |
| 2024 Q1 | 14,613,555 | $76,690,483 | -$1,575,877 | $5.28 | 41 |
| 2023 Q4 | 14,910,095 | $76,226,105 | +$50,694,989 | $5.14 | 45 |
| 2023 Q3 | 3,003,814 | $15,739,243 | +$10,117,983 | $5.24 | 34 |
| 2023 Q2 | 966,706 | $1,807,113 | +$1,807,113 | $1.87 | 30 |